Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT00830414 | Medroxyprogesterone Acetate Injection 150 mg/1 mL in Postmenopausal Women | PHASE1 | COMPLETED | 124 | — | — | Apr 1, 2002 | Sep 1, 2002 | Aug 19, 2024 | 1 | Germany |
| Arm | Type | Description |
|---|---|---|
| 1 | EXPERIMENTAL | - |
| 2 | ACTIVE_COMPARATOR | DEPO-PROVERA® |
| Name | Type | Description |
|---|---|---|
| medroxyprogesterone acetate | DRUG | IM Injection |
Inclusion Criteria * Screening Demographics: All volunteers selected for this study will be healthy postmenopausal women 45 years of age or older at the time of dosing. The weight range will not exceed ±20% for height and body frame as per Desirable Weights for Women - 1983 Metropolitan Height and ...